Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A market-wide retreat in biotech stocks is weighing on Moderna, but analysts cited upcoming company and partner catalysts that could help stabilize sentiment.
THE APEX TIMES
THE APEX TIMES
BioPharma Dive’s latest data-visualization installment highlights Moderna’s sharp run in 2026 and points to a separate spike in deal activity involving Roche, underscoring how quickly sentiment can shift in biotech.
THE APEX TIMES
Moderna shares have surged more than 650% this year, drawing renewed attention to the company’s cancer-vaccine pipeline. But a key sticking point remains: analyst price targets referenced in a recent market report still look far below where the stock is trading.
THE APEX TIMES
A market recap points to Moderna’s recent FDA progress on an mRNA flu vaccine alongside an expanding oncology effort, while Vertex’s latest quarter highlighted a broader pipeline and a raised full-year outlook.
THE APEX TIMES
The biotechnology company will report its third-quarter 2026 results with a live conference call and webcast scheduled for 8:00 a.m. ET on Friday, November 6, 2026.
THE APEX TIMES
A new comparison circulating on Yahoo Finance frames Moderna’s market value as more than three times BioNTech’s, reigniting a question for investors: does scale in mRNA platforms translate into better equity outcomes?
THE APEX TIMES
Moderna’s stock rose sharply after market coverage said the U.S. National Institutes of Health is backing a “COVID-style” effort aimed at accelerating cancer vaccines. The company did not provide additional details in the coverage that triggered the move.
THE APEX TIMES
Moderna (MRNA) closed at $213.63, falling 5.05% from the prior trading session, in a move the latest market report said was larger than the broader market’s decline.
THE APEX TIMES
Moderna’s shares have dramatically outperformed the broader market over the past year, yet the company’s revenue has been shrinking for three straight years, keeping attention on where future growth could be generated.
